Regarding SIRT1 activation, it has been demonstrated that CRC at doses between 20 and 50 mg/kg also promotes the stimulation of the SIRT1/Nrf2 pathway and inhibits Toll-like receptor 4 (TLR4) expression in newborn rats. The gene discussed is NFE2L2; the disease is colorectal carcinoma.